Journal of Pharmacology and Drug Development
Login
JPDD
  • Home
  • Articles & Issues
    • Latest Issue
    • All Issues
  • Authors
    • Submit Manuscript
    • Guide for Authors
    • Author Resources
    • Authorship
    • Article Processing Charges (APC)
  • Reviewers
    • Guide for Reviewers
    • Reviewer Resources
    • Become a Reviewer
  • About
    • About Journal
    • Aims and Scope
    • Editorial Team
    • Journal Insights
    • Peer Review Process
    • Publication Ethics
    • Plagiarism
    • Allegations of Misconduct
    • Appeals and Complaints
    • Corrections and Withdrawals
    • Open Access
    • Archiving Policy
    • Announcements
    • Contact

Search Results for synthesis

Article
Green Synthesis and Characterization of Gold Nanoparticles from Beta vulgaris L. and Their Cytotoxicity Against MDA-MB-231 and MCF-7 Cancer Cells

Abulfadhel Yahya Al-khafaji, Jenan Hussein Taha, Ibramim Abdullah Mahmood

Pages: 210-222

PDF Full Text
Abstract

With the increasing applications of gold nanoparticles in cancer treatment and medical delivery, it has become necessary to study the biological effects of gold nanoparticles. The study aimed to evaluate the biological effects of gold nanoparticles against the mcf-7 & mda-mb-231 cell line. Gold nanoparticles were characterized using several analytical techniques including X-ray Diffraction (XRD), Ultraviolet-Visible Spectroscopy (UV-VIS), Energy Dispersion X-ray (EDX), Atomic Force Microscopy (AFM), and Filed Emission Scanning Electron Microscopy (FE-SEM).. The characterization results confirmed the successful synthesis of high purity quasi-spherical gold nanoparticles with particle sizes ranging from 38 to 59 nm. The cytotoxic effect of the synthesized AuNPs was investigated using the MTT assay on both MCF-7 and MDA-MB-231 cell lines at six different concentrations. The results indicated a concentration-dependent inhibitory effect of gold nanoparticles on both cancer cell lines, with a high cytotoxic activity observed against the MDA-MB-231 cell line. The results of this study indicate the potential use of gold nanoparticles against various types of cancer cell lines, as well as the potential use of gold nanoparticles in treating cancerous diseases with vivo cell.

Article
A Review: Schiff Bases as Promising Agents and Their Pharmaceutical Applications

Ahmed Kamil, Mohammed Jassim Hamzah

Pages: 111-123

PDF Full Text
Abstract

Schiff bases have been a very important category of chemical molecules in medicine and pharmacology over the last several decades. Their structure contains an azomethine functional group (-C=N-).This group is typically formed by the condensation of primary amines with aldehydes or ketones. Schiff bases are relatively easy to synthesize, and their structural versatility allows modification for diverse biological applications. From a medicinal standpoint, Schiff bases have demonstrated a wide range of biological activities, including antimicrobial, anticancer, anti-inflammatory, antioxidant, and antiviral effects.Multiple studies suggest that even small alterations in chemical structure, such changes in substituent characteristics or the introduction of heterocyclic groups, may substantially affect biological efficacy. Schiff bases are also recognized for their ability to coordinate with metal ions, which has led to the development of numerous metal complexes with new or improved pharmacological characteristics.The medicinal significance of Schiff bases is further supported by their proposed mechanisms of action, including enzyme inhibition, interaction with microbial cell membranes, DNA binding, and modulation of oxidative stress pathways.These characteristics make Schiff bases attractive frameworks for the development of novel therapeutic agents.This review aims to highlight the pharmaceutical importance of Schiff bases by focusing on their chemical characteristics and key antibacterial, antifungal, antiviral, and anticancer activities, while also discussing their potential applications in drug discovery and development.

Article
In-Silico Profiling of New Mefenamic Acid Derivatives as HDAC 8 Inhibitors

Zainab Ali, Mohammed J Hamzah, Ameer H. Alwash

Pages: 34-48

PDF Full Text
Abstract

Vital cellular processes such as, proliferation and tumor progression were reported to be centrally controlled by histone deacetylase (HDAC) enzymes which make them an interesting therapeutic target. Recently, a new paradigm has attracted researches to combine nonsteroidal anti-inflammatory drugs (NSAIDs) with para-aminobenzoic acid (PABA) and a zinc binding group (ZBG), presenting a synergistic impact on HDAC activity and inflammatory process. In the current study, a novel series of hybrid compounds (A1-6) were designed and evaluated for their HDAC binding affinity by molecular docking technique along with conducting an in-silico ADME (absorption, distribution, metabolism, and elimination) profiling to assess their pharmacokinetic characteristics. Compound A6 displayed the highest binding energy score (-9.539 kcal/mol) with the active site of HDAC 8 enzyme compared with the reference ligand, SAHA (-4.606 kcal/mol). Its worth mentioning that compound A6 has comparable coordination to the catalytic zinc ion with SAHA along with engaging additional hydrophobic and aromatic interaction within the active site of HDAC 8 enzyme. ADME analysis predicated high gastrointestinal absorption for A2, A5, and A6, which also comply with Lipinski's rule, indicating good oral bioavailability. Conversely, A1, A3, and A4 showed moderate absorption, suitable for parenteral or localized/colon-targeted delivery, potentially advantageous for colon cancer treatment. These results highlight these hybrids’ potential as HDAC inhibitors and support further synthesis and biological testing.

1 - 3 of 3 items

Search Parameters

×

The submission system is temporarily under maintenance. Please send your manuscripts to

Go to Editorial Manager
Journal Logo
Journal of Pharmacology and Drug Development

College of Pharmacy | Al-Nahrain University

  • Copyright Policy
  • Terms & Conditions
  • Privacy Policy
  • Accessibility
  • Cookie Settings
Licensing & Open Access

CC BY 4.0 Logo Licensed under CC-BY-4.0

This journal provides immediate open access to its content.

Editorial Manager Logo Elsevier Logo

Peer-review powered by Elsevier’s Editorial Manager®

Copyright © 2026 College of Pharmacy, Al-Nahrain University, its licensors, and contributors. All rights reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.